Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Berlin , Germany , United States , California , April Armstrong , Roland Chen , Bristol Myers Squibb , Los Angeles , European Academy Of Dermatology , Facebook , Clinical Trial Program , Youtube , Exchange Commission , Twitter , Linkedin , Instagram , Neuroscience Development , University Of California , Program To , Laboratory Abnormalities , Bristol Myers Squibb Company Adverse Event , Amgen Inc , Venereology Congress , Psoriasis Area , Severity Index , Myers Squibb , Global Assessment , European Academy , Bristol Myers , Pioneering Paths Forward , Transform Patient , Risks Related , Janus Kinase , Bristol Myers Squibb Company , Adverse Event , Prescribing Information , Medication Guide , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,